Literature DB >> 9667653

Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.

M Santala1, J Risteli, L Risteli, U Puistola, B M Kacinski, E R Stanley, A Kauppila.   

Abstract

The synthesis and degradation of type I and type III interstitial collagens releases several antigenic metabolites, whose measurement allows the metabolism of connective tissue to be evaluated under a variety of different conditions. In this study we investigated the influence of benign and malignant ovarian neoplasms on the metabolism of these collagens. The study population comprised patients with benign (n = 53), borderline (n = 6) or malignant (n = 36) ovarian neoplasms. We quantified the serum, cyst fluid and peritoneal/ascitic fluid concentrations of the amino-terminal propeptide of type I (PINP) and III (PIIINP) procollagens, indicators of the synthesis of type I and III collagen, respectively and the cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), an indicator of type I collagen degradation. Macrophage colony-stimulating factor 1 (CSF-1) concentration was also assayed as its serum level is increased in ovarian cancer and CSF-1 may be involved in the regulation of collagen metabolism. The concentration of each antigen was significantly higher in patients with malignant tumour than with benign neoplasm in each comparison, except for ICTP in peritoneal fluid and for CSF-1 in cyst fluid. The high ascitic fluid concentration of PINP, PIIINP or CSF-1 correlated with malignancy, and the low cyst fluid concentration of any of the four markers was indicative of benign tumour. Levels of CSF-1 did not correlate with the levels of any of the markers of collagen turnover. The concentration of PINP in ascites was about 50 times higher and in cyst fluid about eight times higher than that in the serum from patients with malignant tumour, whereas the respective ratios for ICTP were only 2.5 and 1.3. In such patients, the ratio of ascitic fluid to serum concentration was also about 80-fold higher for PIIINP and about 20-fold higher for PINP than for ICTP. The different distributions of PIIINP, PINP and ICTP suggests dominance of synthetic processes or retarded elimination of PIIINP and PINP in ovarian cancer. In advanced malignancies, the accumulation of PINP and PIIINP in abdominal space, possibly due to increased synthesis and/or failed resorption, may promote ascites formation. This study shows that both accelerated synthesis and breakdown of fibrillar collagens are characteristic of ovarian malignancy, and suggests that measurements of cyst fluid or ascitic fluid concentrations of collagen metabolites or CSF-1 could be used in the differential diagnosis of benign and malignant ovarian neoplasms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667653      PMCID: PMC2150318          DOI: 10.1038/bjc.1998.303

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?

Authors:  L Risteli; A Kauppila; U M Mäkilä; J Risteli
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

Review 2.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

Review 3.  Collagen propeptides as indicators of collagen assembly.

Authors:  J Risteli; S Niemi; S Kauppila; J Melkko; L Risteli
Journal:  Acta Orthop Scand Suppl       Date:  1995-10

Review 4.  Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects.

Authors:  J Risteli; L Risteli
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

5.  Collagen fibrillogenesis in human skin.

Authors:  R Fleischmajer; J S Perlish; R Timpl
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

6.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.

Authors:  J Risteli; S Niemi; P Trivedi; O Mäentausta; A P Mowat; L Risteli
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

7.  Immunoassay for intact amino-terminal propeptide of human type I procollagen.

Authors:  J Melkko; S Kauppila; S Niemi; L Risteli; K Haukipuro; A Jukkola; J Risteli
Journal:  Clin Chem       Date:  1996-06       Impact factor: 8.327

Review 8.  Connective tissue as an active participant in the process of malignant growth.

Authors:  A Van den Hooff
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

9.  Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.

Authors:  H S Gilbert; V Praloran; E R Stanley
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

10.  Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer.

Authors:  A Kauppila; U Puistola; J Risteli; L Risteli
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

View more
  7 in total

1.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  UFFizi: a generic platform for ranking informative features.

Authors:  Assaf Gottlieb; Roy Varshavsky; Michal Linial; David Horn
Journal:  BMC Bioinformatics       Date:  2010-06-03       Impact factor: 3.169

3.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers.

Authors:  Kathleen Hibbs; Keith M Skubitz; Stefan E Pambuccian; Rachael C Casey; Kathryn M Burleson; Theodore R Oegema; Jeannine J Thiele; Suzanne M Grindle; Robin L Bliss; Amy P N Skubitz
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 4.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

5.  Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope.

Authors:  Jennifer M Caron; Jacquelyn J Ames; Liangru Contois; Leonard Liebes; Robert Friesel; Franco Muggia; Calvin P H Vary; Leif Oxburgh; Peter C Brooks
Journal:  Am J Pathol       Date:  2016-06       Impact factor: 4.307

6.  Clinical significance and biological role of cancer-derived Type I collagen in lung and esophageal cancers.

Authors:  Shuo Fang; Yongdong Dai; Yan Mei; Mingming Yang; Liang Hu; Hong Yang; Xininyuan Guan; Jiangchao Li
Journal:  Thorac Cancer       Date:  2019-01-03       Impact factor: 3.500

7.  A comparative analysis of different biofluids towards ovarian cancer diagnosis using Raman microspectroscopy.

Authors:  Panagiotis Giamougiannis; Camilo L M Morais; Rita Grabowska; Katherine M Ashton; Nicholas J Wood; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Anal Bioanal Chem       Date:  2020-11-26       Impact factor: 4.142

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.